Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

BEYOND COVID -19 AND OTHER RESPIRATORY SYSTEM DISEASES, WHAT’S NEXT DR. JAVITT??? Cardiac fibrosis commonly refers to the excess deposition of extracellular matrix in the cardiac muscle, but the term may also refer to an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts.

https://en.wikipedia.org/wiki/Cardiac_fibrosis

The concentration of vasoactive intestinal peptide (VIP) in the heart has been shown to decrease as fibrosis (the pathology leading to heart failure) increases and to become undetectable in end stage cardiomyopathy.

https://pubmed.ncbi.nlm.nih.gov/31449808/

We conclude that VIP infusion increased myocardial VIP concentration and was able to reverse existing myocardial fibrosis suggesting a possible therapeutic role for a VIP based therapy in cardiac failure.

https://pubmed.ncbi.nlm.nih.gov/31449808/

CAN WE GET A PIECE OF THE ACTION IN THIS MARKET???
The global cystic fibrosis therapeutics market is expected to reach USD 13.9 billion by 2025, according to a new report by Grand View Research, Inc.

https://www.grandviewresearch.com/press-release/global-cystic-fibrosis-cf-therapeutics-market

WILL WE HAVE ENOUGH VIP “ROCKET PROPELLANT” FOR OUR TIMELESS FLIGHT???

"OUR FAVORITE HOLDING PERIOD IS FOREVER.”
- Warren Buffett